BCL2 and cancer: We investigated how TZB induces the apoptosis of cancer cells [75] by inhibiting Bcl-2 in the intracellular (NF-κB, Bcl-2 and BAX) system (Figs 3 and 4) and how up-regulation of IL-6 from long term TZB treatment [22] can induce activation of NF-κB which in turn induces up-regulation of Bcl-2 and down-regulation of BAX, switching the apoptotic mode to anti-apoptotic mode (Fig 4).